PM54-1 

PM54 is an antitumor agent with activity across multiple cancer types. PM54 acts as a transcription and WNT/β-catenin signaling pathway inhibitor. PM54 suppresses oncogenic transcriptional programs, and key malignant pathways, while inducing DNA double-strand breaks, S-phase cell cycle arrest and apoptosis. PM54 enhances innate immune recognition, remodels the tumor microenvironment. PM54 exhibits antitumor activity as monotherapy or in combination in xenograft models. PM54 is applicable to research on various cancers and advanced solid tumors^[1][2][3].

PM54 (50 nM; 6 h) induces a conserved pan-cancer transcriptional repression program targeting cell cycle, chromatin regulation, and DNA repair in 32 diverse cancer cell lines, with primed responders (characterized by strong suppression of MYC, mTOR, cell cycle, and DNA repair pathways, often with intact TP53 function) exhibiting a more robust transcriptomic response than adaptive responders^[1].
PM54 (6-18 h) inhibits WNT/β-catenin-driven transcription in gastric cancer cell lines, reducing activity by ~40% at 6 h and >70% at 18 h^[2].
PM54 exhibits strong synergy with 5-fluorouracil in HGC-27 and Hs746T diffuse-type gastric cancer cell lines, and with Cisplatin (HY-17394) in HGC-27 cells^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

PM54 enhances survival in multiple CDX cancer models, with primed responder models showing the most durable therapeutic outcomes^[1].
PM54 (1.2 mg/kg; i.v.; once weekly; 16 days) exhibits strong antitumor activity in soft tissue sarcoma xenograft models, with the most significant effect in the STS134 model where it reduces tumor volume to 76% of baseline^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

785.86

C₄₁H₄₃N₃O₁₁S

2248127-86-6

CC(C1=C2OCO1)=C(OC(C)=O)C3=C2[C@H](CO4)N([C@@H](O)C5N(C)C6C7=C(C=C(C)C(OC)=C7O)C5)[C@@]6([H])[C@@H]3SC[C@](C8=C9C%10=CC=CC=C%10O8)(N[C@H](CO)C9)C4=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Fernández-Miranda I, et al. PM54 targets oncogenic transcriptional networks across multiple cancer types. Cancer Res. 2026;86(7 Suppl):Abstract 2981.

  [2]. Gutierrez Alvarez FJ, et al. PM54 suppresses WNT/β-catenin signaling and synergizes with chemotherapy in gastric cancer models. Cancer Res. 2026;86(7 Suppl):Abstract 5754.

  [3]. Gorgels D, et al. The next generation transcriptional inhibitor PM54 demonstrates strong antitumor activity in patient-derived xenograft models of soft tissue sarcoma. Cancer Res. 2025;85(8 Suppl 1):Abstract 6858.